Physician profile
April Fields
NPI 1265048615
$1,078.38
in general payments reported to CMS, 2019-2025
18 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2024: $194 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.01 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.41 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $217.86 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.84 | 2024-2025 | Caplyta |
| Tonix Medicines, INC. | $61.92 | 2025 | Tonmya |
| Indivior INC. | $60.08 | 2025 | Sublocade |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.22 | 2025 | Rexulti |
| Amgen INC. | $47.92 | 2024-2025 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.02 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $42.08 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Phathom Pharmaceuticals, INC. | $38.00 | 2024 | Voquezna |
| Grifols USA, LLC | $25.18 | 2025 | Prolastin-C Liquid |
| Alkermes, INC. | $22.78 | 2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $18.72 | 2025 | Auvelity |
| Ardelyx, INC. | $17.54 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $14.88 | 2024 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.86 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $13.96 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.